Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

The introduction of biologic agents, especially rituximab (RTX), a chimeric monoclonal antibody targeting CD20+ B cells, has revolutionized the treatment landscape. This review synthesized the current ...

Background: Rituximab (RTX) is a monoclonal antibody that has been increasingly used in the treatment of myasthenia gravis (MG). In most studies, the therapeutic protocol of RTX has been similar to ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

She was admitted to hospital as an emergency with prolonged and painful extensor spasms affecting the neck and back, arms, and legs. The disease had progressed despite a favourable initial response to ...

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

JAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in ...

Most patients were able to stay with treatment once starting it, with retention rates of about 60% to 80% through 12 months (rituximab had the highest retention and IL-6 inhibitors the lowest).